TY - JOUR
T1 - Animal models for arthritis
T2 - Innovative tools for prevention and treatment
AU - Kollias, George
AU - Papadaki, Piyi
AU - Apparailly, Florence
AU - Vervoordeldonk, Margriet J.
AU - Holmdahl, Rikard
AU - Baumans, Vera
AU - Desaintes, Christian
AU - Di Santo, James
AU - Distler, Jörg
AU - Garside, Paul
AU - Hegen, Martin
AU - Huizinga, Tom W.J.
AU - Jüngel, Astrid
AU - Klareskog, Lars
AU - McInnes, Iain
AU - Ragoussis, Ioannis
AU - Schett, Georg
AU - Hart, Ber T.T.
AU - Tak, Paul P.
AU - Toes, Rene
AU - Van Den Berg, Wim
AU - Wurst, Wolfgang
AU - Gay, Steffen
PY - 2011/8
Y1 - 2011/8
N2 - The development of novel treatments for rheumatoid arthritis (RA) requires the interplay between clinical observations and studies in animal models. Given the complex molecular pathogenesis and highly heterogeneous clinical picture of RA, there is an urgent need to dissect its multifactorial nature and to propose new strategies for preventive, early and curative treatments. Research on animal models has generated new knowledge on RA pathophysiology and aetiology and has provided highly successful paradigms for innovative drug development. Recent focus has shifted towards the discovery of novel biomarkers, with emphasis on presymptomatic and emerging stages of human RA, and towards addressing the pathophysiological mechanisms and subsequent efficacy of interventions that underlie different disease variants. Shifts in the current paradigms underlying RA pathogenesis have also led to increased demand for new (including humanised) animal models. There is therefore an urgent need to integrate the knowledge on human and animal models with the ultimate goal of creating a comprehensive 'pathogenesis map' that will guide alignment of existing and new animal models to the subset of disease they mimic. This requires full and standardised characterisation of all models at the genotypic, phenotypic and biomarker level, exploiting recent technological developments in '-omics' profiling and computational biology as well as state of the art bioimaging. Efficient integration and dissemination of information and resources as well as outreach to the public will be necessary to manage the plethora of data accumulated and to increase community awareness and support for innovative animal model research in rheumatology.
AB - The development of novel treatments for rheumatoid arthritis (RA) requires the interplay between clinical observations and studies in animal models. Given the complex molecular pathogenesis and highly heterogeneous clinical picture of RA, there is an urgent need to dissect its multifactorial nature and to propose new strategies for preventive, early and curative treatments. Research on animal models has generated new knowledge on RA pathophysiology and aetiology and has provided highly successful paradigms for innovative drug development. Recent focus has shifted towards the discovery of novel biomarkers, with emphasis on presymptomatic and emerging stages of human RA, and towards addressing the pathophysiological mechanisms and subsequent efficacy of interventions that underlie different disease variants. Shifts in the current paradigms underlying RA pathogenesis have also led to increased demand for new (including humanised) animal models. There is therefore an urgent need to integrate the knowledge on human and animal models with the ultimate goal of creating a comprehensive 'pathogenesis map' that will guide alignment of existing and new animal models to the subset of disease they mimic. This requires full and standardised characterisation of all models at the genotypic, phenotypic and biomarker level, exploiting recent technological developments in '-omics' profiling and computational biology as well as state of the art bioimaging. Efficient integration and dissemination of information and resources as well as outreach to the public will be necessary to manage the plethora of data accumulated and to increase community awareness and support for innovative animal model research in rheumatology.
UR - http://www.scopus.com/inward/record.url?scp=79959808736&partnerID=8YFLogxK
U2 - 10.1136/ard.2010.148551
DO - 10.1136/ard.2010.148551
M3 - Review article
C2 - 21628308
AN - SCOPUS:79959808736
SN - 0003-4967
VL - 70
SP - 1357
EP - 1362
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 8
ER -